The estimated Net Worth of Stephen J Tulipano is at least $1.54 Million dollars as of 15 March 2024. Mr. Tulipano owns over 13,100 units of Stoke Therapeutics stock worth over $366,466 and over the last 10 years he sold STOK stock worth over $0. In addition, he makes $1,176,400 as Chief Financial Officer at Stoke Therapeutics.
Stephen has made over 5 trades of the Stoke Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 13,100 units of STOK stock worth $193,094 on 15 March 2024.
The largest trade he's ever made was exercising 70,000 units of Stoke Therapeutics stock on 2 November 2020 worth over $313,600. On average, Stephen trades about 7,505 units every 152 days since 2014. As of 15 March 2024 he still owns at least 24,862 units of Stoke Therapeutics stock.
You can see the complete history of Mr. Tulipano stock trades at the bottom of the page.
Stephen J. Tulipano CPA serves as Chief Financial Officer of the Company. From June 2014 to July 2018, Mr. Tulipano served as Chief Financial Officer and Treasurer of Aldeyra Therapeutics, Inc., a biotechnology company. From January 2011 to June 2014, Mr. Tulipano served in an accounting and management advisory role at Three Tulips, Inc. Previously, Mr. Tulipano was Chief Financial Officer and Secretary of Javelin Pharmaceuticals, Inc. Mr. Tulipano holds a B.S. from Salem State College and an M.B.A. from Suffolk University. He is a Certified Public Accountant.
As the Chief Financial Officer of Stoke Therapeutics, the total compensation of Stephen Tulipano at Stoke Therapeutics is $1,176,400. There are no executives at Stoke Therapeutics getting paid more.
Stephen Tulipano is 60, he's been the Chief Financial Officer of Stoke Therapeutics since 2019. There are 10 older and 9 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.
Stephen's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic... und Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics executives and other stock owners filed with the SEC include: